Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Yonsei Liver Center, Severance Hospital, Seoul, Korea.
Cancer Res Treat. 2019 Oct;51(4):1347-1356. doi: 10.4143/crt.2018.477. Epub 2019 Feb 12.
Conditional survival estimates (CSE) can provide additional useful prognostic information on the period of survival after diagnosis, which helps in counseling patients with cancer on their individual prognoses. This study aimed to analyze conditional survival (CS) for hepatocellular carcinoma (HCC) using a Korean national registry.
Patients with HCC, registered in the Korean cancer registry database, were retrospectively reviewed. Overall survival (OS) was calculated using the Kaplan-Meier method. The 1-year CS at X year or month after diagnosis were calculated as CS1=OS(X+1)/OS(X). CS calculations were performed in each Barcelona Clinic Liver Cancer stage, after which patients at stage 0, A, and B underwent subgroup analysis using initial treatment methods.
A total of 4,063 patients diagnosed with HCC from January 2008 to December 2010, and 2,721 who were diagnosed from January 2011 to December 2012, were separately reviewed. In 2008-2010, the 1-year CS of 1, 2, 3, 4, and 5-year survivors was 82.9%, 85.1%, 88.3%, 88.0%, and 88.6%, respectively. Patients demonstrated an increase in CSE over time in subgroup analysis, especially in the advanced stages. In 2011-2012, the 1-year CS of 6, 12, 18, 24, 30, and 36 months was 81.5%, 83.8%, 85.3%, 85.5%, 86.5%, and 88.8%, respectively. The subgroup analysis showed the same tendency towards increased CSE in the advanced stages.
Overall, the CS improved with each additional year after diagnosis in both groups. CSE may therefore provide a more accurate prognosis and hopeful message to patients who are surviving with or after treatment.
条件生存估计(CSE)可以为诊断后生存期间提供额外的有用预后信息,有助于为癌症患者提供个体预后咨询。本研究旨在使用韩国国家登记处分析肝细胞癌(HCC)的条件生存(CS)。
回顾性分析了登记在韩国癌症登记数据库中的 HCC 患者。使用 Kaplan-Meier 方法计算总生存(OS)。诊断后 X 年或 X 个月的 1 年 CS 计算为 CS1=OS(X+1)/OS(X)。在每个巴塞罗那临床肝癌分期中进行 CS 计算,然后对 0 期、A 期和 B 期患者根据初始治疗方法进行亚组分析。
分别对 2008 年 1 月至 2010 年 12 月和 2011 年 1 月至 2012 年 12 月诊断为 HCC 的 4063 例和 2721 例患者进行了回顾性分析。在 2008-2010 年,1 年 CS 的 1 年、2 年、3 年、4 年和 5 年生存率分别为 82.9%、85.1%、88.3%、88.0%和 88.6%。亚组分析显示,随着时间的推移,患者的 CSE 逐渐增加,尤其是在晚期。在 2011-2012 年,6 个月、12 个月、18 个月、24 个月、30 个月和 36 个月的 1 年 CS 分别为 81.5%、83.8%、85.3%、85.5%、86.5%和 88.8%。亚组分析显示,晚期患者的 CSE 呈上升趋势。
总的来说,两组患者在诊断后每增加一年,CS 均有所提高。因此,CSE 可能为治疗后生存的患者提供更准确的预后和更有希望的信息。